Reducing human suffering by detecting cancer earlier with patented technology

BioCurex's RECAF(tm) marker is found in all types of major cancers

Free
Message: A MUST READ

A MUST READ

posted on Jul 12, 2009 03:17PM

This post copied from Investorshub explains a lot about Goldseeker and sheds some light on the reasons for his relentless bashing of Biocurex and it's technology. As I've stated several times in past post he does fit the profile of a basher because he is one. As I suspected for some time this guy is a professional trying to steal your shares. I wanted to post Mati Hari's post here in case the post was deleted. Don't let Goldseeker steal your shares!

JMHO

hari, the lateral flow space seems to be indeed locked up between inverness and abbott as stated in the chembio 07 annual report:

"Prior to the issuance of our United States patent covering our Dual Path Platform (DPP™), we owned no issued patents covering lateral flow technology. Therefore we obtained non-exclusive licenses from Inverness Medical Innovations, Inc. and Abbott Laboratories with respect to their portfolios of single path lateral flow patents."

per your other question, i think you have to look at the body of work of each anonymous poster to determine their actual motives--most posters on this board are posting for their trading book.

a prolific poster on this board has been exposed by yours truly. he/she/it/they erred in posting conflicting personal data--the poster's age in this case.

also, the same poster gave tacit approval of the lastest pr in the morning of its release. during which churning appeared to be taking place to entice investers to buy a inflated prices and then sell short.

this kind of manipulative trading is not uncommon. some officer of ihub has recently been accused by the sec of such. the father and wife of the person of brett salter mentioned in the filings were convicted of such in the late 90's.

so you see hari, this space has long been unattended until now.

yours truly,

mr. mata

Share
New Message
Please login to post a reply